Biotech

Relmada dumps depression asset after slew of phase 3 failures

The biotech has terminated the license agreement for esmethadone, months after canceling two phase 3 trials that were not expected to hit their goals.

Darren Incorvaia Jul 11, 2025 12:12pm

3D Binoculars with Question Mark Cubes - Colored Background - 3D Rendering

Karyopharm lays off 20% of staffers amid hunt for alternatives

Jul 11, 2025 11:02am

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm

Fierce Biotech Layoff Tracker 2025: Century, Karyopharma & more

Jul 11, 2025 10:00am

Guidehouse’s Karla Anderson shares top tips for successful biotech commercialization

Oct 28, 2024 8:00am

Graphic image of a red thumbs down against a blue background

FDA rejects Capricor’s DMD cell therapy, asks for more data

Jul 11, 2025 9:18am